123 related articles for article (PubMed ID: 38606933)
21. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
22. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
[TBL] [Abstract][Full Text] [Related]
23. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
24. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Jayaprakash P; Ai M; Liu A; Budhani P; Bartkowiak T; Sheng J; Ager C; Nicholas C; Jaiswal AR; Sun Y; Shah K; Balasubramanyam S; Li N; Wang G; Ning J; Zal A; Zal T; Curran MA
J Clin Invest; 2018 Nov; 128(11):5137-5149. PubMed ID: 30188869
[TBL] [Abstract][Full Text] [Related]
25. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
26. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
27. Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate.
Liu W; Zhu Y; Ye L; Zhu Y; Wang Y
BMC Cancer; 2022 Feb; 22(1):173. PubMed ID: 35168543
[TBL] [Abstract][Full Text] [Related]
28. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Mazzoleni S; Jachetti E; Morosini S; Grioni M; Piras IS; Pala M; Bulfone A; Freschi M; Bellone M; Galli R
Stem Cells Transl Med; 2013 Sep; 2(9):678-89. PubMed ID: 23884639
[TBL] [Abstract][Full Text] [Related]
29. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
30. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
32. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
[TBL] [Abstract][Full Text] [Related]
33. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
34. A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.
Yu SH; Maynard JP; Vaghasia AM; De Marzo AM; Drake CG; Sfanos KS
Prostate; 2019 Feb; 79(2):215-222. PubMed ID: 30345534
[TBL] [Abstract][Full Text] [Related]
35. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
37. Experimental orthotopic prostate tumor in nude mice: techniques for local cell inoculation and three-dimensional ultrasound monitoring.
Saar M; Körbel C; Jung V; Suttmann H; Grobholz R; Stöckle M; Unteregger G; Menger MD; Kamradt J
Urol Oncol; 2012; 30(3):330-8. PubMed ID: 20452251
[TBL] [Abstract][Full Text] [Related]
38. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
39. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.
Berman-Booty LD; Thomas-Ahner JM; Bolon B; Oglesbee MJ; Clinton SK; Kulp SK; Chen CS; La Perle KM
Toxicol Pathol; 2015 Feb; 43(2):186-97. PubMed ID: 24742627
[TBL] [Abstract][Full Text] [Related]
40. Tumorigenic potential of circulating prostate tumor cells.
Carvalho FL; Simons BW; Antonarakis ES; Rasheed Z; Douglas N; Villegas D; Matsui W; Berman DM
Oncotarget; 2013 Mar; 4(3):413-21. PubMed ID: 23530114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]